The trademark application TYCRAVA was filed by Bristol-Myers Squibb Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on March 24, 2021, and it was registered by office on July 1, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).